Amphastar Pharmaceuticals AMPH FR — Revenue
Other geography segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's fr — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's FR — revenue?
- Amphastar Pharmaceuticals (AMPH) reported FR — revenue of $9.65M in Q1 2026.
- How has Amphastar Pharmaceuticals's FR — revenue changed year-over-year?
- Amphastar Pharmaceuticals's FR — revenue increased by 22.8% year-over-year, from $7.86M to $9.65M.
- What is the long-term trend for Amphastar Pharmaceuticals's FR — revenue?
- Over 4 years (2021 to 2025), Amphastar Pharmaceuticals's FR — revenue has grown at a 31.3% compound annual growth rate (CAGR), from $11.88M to $35.28M.
- What does FR — revenue mean?
- This metric represents the total gross sales generated by the specific geographic or product segment identified as FR. It reflects the market demand and commercial success of the company's offerings within this defined operational area. Monitoring this figure helps investors assess the growth trajectory and revenue contribution of this specific business unit relative to the company's total consolidated performance.